|
Q3 FY2026
As of Sep 26, 2026
|
Q2 FY2026
As of Jun 27, 2026
|
Q1 FY2026
As of Mar 28, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
|
|---|---|---|---|---|
| ASSETS | ||||
| Current assets | ||||
| Cash and cash equivalents | ||||
| Short-term investments | ||||
| Trade accounts receivable, net of allowance for credit losses of $148 and $152 as of September 26, 2026 and December 31, 2025, respectively | ||||
| Inventories | ||||
| Other current assets | ||||
| Total current assets | ||||
| Property, plant, and equipment, net | ||||
| Other non-current assets | ||||
| Goodwill | ||||
| Intangible assets, net | ||||
| Deferred tax assets | ||||
| Other long-term assets | ||||
| Total other non-current assets | ||||
| Total assets | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||
| Current liabilities | ||||
| Current portion of long-term borrowings and other short-term borrowings | ||||
| Accounts payable | ||||
| Accrued expenses and other current liabilities | ||||
| Total current liabilities | ||||
| Non-current liabilities | ||||
| Long-term borrowings, less current portion | ||||
| Tax receivable agreement liability | ||||
| Other long-term liabilities | ||||
| Total non-current liabilities | ||||
| Total liabilities | ||||
| Mezzanine equity | ||||
| Stockholders’ equity | ||||
| Common stock | ||||
| Preferred stock | ||||
| Additional paid-in capital | ||||
| Retained earnings (accumulated deficit) | ||||
| Accumulated other comprehensive (loss) income | ||||
| Total Medline Inc. stockholders’ equity | ||||
| Noncontrolling interests | ||||
| Total stockholders’ equity | ||||
| Total liabilities and stockholders’ equity |
Loading...